PacBio

The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications.

Eremid® Genomic Services, LLC (“Eremid”) announces a significant expansion of its in-house sequencing capabilities with the installation of PacBio’s latest HiFi sequencing platform, the Revio.

Bioscientia acquires multiple Revio sequencing systems to revolutionize rare disease research by sequencing thousands of long-read human genomes annually.

A study demonstrated that long-lived tropical trees accumulate more somatic mutations, providing insights into potential mechanisms underlying genetic variation.

In this opinion piece, Neil Ward discusses how the passing of the Genetic Technology "Precision Breeding" Bill could support global efforts to increase food production sustainably.

An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.

The Revio system adds affordability, high throughput, and ease of use to a foundation of long
reads, exceptional accuracy, and direct methylation detection. Get reads that are tens of
kilobases in length with >Q30 scores and complete phased genomes for <$1,000, all with 50%
fewer consumables.

Long-read sequencing enables the accurate identification and characterization of complex genomic features. It outperforms its short-read alternatives in de novo assembly, mapping, and variant calling applications.

PacBio has announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy.

Scientists have shown that regenerative therapy to restore impaired kidney function may soon be a possibility.